204 related articles for article (PubMed ID: 18808306)
21. Effects of statins vs. non-statin lipid-lowering therapy on bone formation and bone mineral density biomarkers in patients with hyperlipidemia.
Chuengsamarn S; Rattanamongkoulgul S; Suwanwalaikorn S; Wattanasirichaigoon S; Kaufman L
Bone; 2010 Apr; 46(4):1011-5. PubMed ID: 20045497
[TBL] [Abstract][Full Text] [Related]
22. Atorvastatin and simvastatin, but not pravastatin, up-regulate LPS-induced MMP-9 expression in macrophages by regulating phosphorylation of ERK and CREB.
Lee DK; Park EJ; Kim EK; Jin J; Kim JS; Shin IJ; Kim BY; Lee H; Kim DE
Cell Physiol Biochem; 2012; 30(3):499-511. PubMed ID: 22814256
[TBL] [Abstract][Full Text] [Related]
23. Dose-response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies.
Wierzbicki AS; Mikhailidis DP
Int J Cardiol; 2002 Jul; 84(1):53-7. PubMed ID: 12104065
[TBL] [Abstract][Full Text] [Related]
24. Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial.
Bone HG; Kiel DP; Lindsay RS; Lewiecki EM; Bolognese MA; Leary ET; Lowe W; McClung MR
J Clin Endocrinol Metab; 2007 Dec; 92(12):4671-7. PubMed ID: 17726081
[TBL] [Abstract][Full Text] [Related]
25. Statins for the treatment of dementia.
McGuinness B; O'Hare J; Craig D; Bullock R; Malouf R; Passmore P
Cochrane Database Syst Rev; 2010 Aug; (8):CD007514. PubMed ID: 20687089
[TBL] [Abstract][Full Text] [Related]
26. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the effects of pravastatin and atorvastatin on fracture incidence in the PROVE IT-TIMI 22 trial--secondary analysis of a randomized controlled trial.
Reid IR; Tonkin A; Cannon CP
Bone; 2005 Aug; 37(2):190-1. PubMed ID: 15936996
[TBL] [Abstract][Full Text] [Related]
28. Statins: beneficial or adverse for glucose metabolism.
Sasaki J; Iwashita M; Kono S
J Atheroscler Thromb; 2006 Jun; 13(3):123-9. PubMed ID: 16835466
[TBL] [Abstract][Full Text] [Related]
29. Distinct effects of pravastatin, atorvastatin, and simvastatin on insulin secretion from a beta-cell line, MIN6 cells.
Ishikawa M; Okajima F; Inoue N; Motomura K; Kato T; Takahashi A; Oikawa S; Yamada N; Shimano H
J Atheroscler Thromb; 2006 Dec; 13(6):329-35. PubMed ID: 17192698
[TBL] [Abstract][Full Text] [Related]
30. Toward a role for statins in immunomodulation.
Mach F
Mol Interv; 2002 Dec; 2(8):478-80. PubMed ID: 14993398
[TBL] [Abstract][Full Text] [Related]
31. Potential mechanisms and applications of statins on osteogenesis: Current modalities, conflicts and future directions.
Oryan A; Kamali A; Moshiri A
J Control Release; 2015 Oct; 215():12-24. PubMed ID: 26226345
[TBL] [Abstract][Full Text] [Related]
32. Influence of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors on endothelial nitric oxide synthase and the formation of oxidants in the vasculature.
Parker RA; Huang Q; Tesfamariam B
Atherosclerosis; 2003 Jul; 169(1):19-29. PubMed ID: 12860247
[TBL] [Abstract][Full Text] [Related]
33. An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).
Smith DG; McBurney CR
Pharmacoeconomics; 2003; 21 Suppl 1():13-23. PubMed ID: 12648031
[TBL] [Abstract][Full Text] [Related]
34. Differential metabolic effects of distinct statins.
Koh KK; Sakuma I; Quon MJ
Atherosclerosis; 2011 Mar; 215(1):1-8. PubMed ID: 21130454
[TBL] [Abstract][Full Text] [Related]
35. The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity.
Staal A; Frith JC; French MH; Swartz J; Güngör T; Harrity TW; Tamasi J; Rogers MJ; Feyen JH
J Bone Miner Res; 2003 Jan; 18(1):88-96. PubMed ID: 12510809
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Plans-Rubió P
Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
[TBL] [Abstract][Full Text] [Related]
37. High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production.
Roglans N; Verd JC; Peris C; Alegret M; Vázquez M; Adzet T; Díaz C; Hernández G; Laguna JC; Sánchez RM
Lipids; 2002 May; 37(5):445-54. PubMed ID: 12056585
[TBL] [Abstract][Full Text] [Related]
38. HMG CoA reductase inhibitors and the skeleton: a comprehensive review.
Bauer DC
Osteoporos Int; 2003 Jun; 14(4):273-82. PubMed ID: 12736772
[TBL] [Abstract][Full Text] [Related]
39. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
Yee HS; Fong NT
Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
[TBL] [Abstract][Full Text] [Related]
40. Prospective, double blind, randomized, controlled trial of simvastatin in human fracture healing.
Patil S; Holt G; Raby N; McLellan AR; Smith K; O'Kane S; Beastall G; Crossan JF
J Orthop Res; 2009 Mar; 27(3):281-5. PubMed ID: 18853428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
